logo
  

ELong Forms Special Committee To Consider "going Private" Proposal

eLong, Inc. (LONG), a mobile and online travel service provider in China, said Thursday that its board of directors has formed a special committee consisting of three independent and disinterested directors, May Wu, Shengli Wang and Adam J. Zhao, to consider the non-binding "going private" proposal from Tencent Holdings Ltd. that the Board received on August 3. Ms. May Wu will be the chairman of the special committee.

The special committee plans to retain independent legal and financial advisors in due course, to assist it in the process.


The company also said that it has appointed Chief Executive Officer Hao Jiang as a director and Adam Zhao as an independent director, effective August 10 and August 13, respectively.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Ride-hailing and delivery platform Uber Technologies, Inc. (UBER) reported Wednesday a net loss for the first quarter that sharply widened from last year, hurt by a huge net unrealized loss related to the revaluation of Uber's equity investments. Loss per share for the quarter missed analysts' expectations, while quarterly revenues topped it. Shares of Siemens Energy AG were gaining more than 12 percent in German trading after the company on Wednesday raised its outlook for fiscal 2024 after reporting a profit in its second quarter, compared to last year's loss, amid positive market environment. Meanwhile, second-quarter orders were lower than last year, and the company maintained annual earnings forecast. AstraZeneca, a major provider of Covid-19 vaccines across the world mainly during the initial pandemic period, has initiated a process to withdraw its Vaxzevria COVID-19 vaccine worldwide, citing weak demand and the surplus availability of new vaccines. Meanwhile, AstraZeneca reportedly had admitted recently in court documents that the vaccine could cause side-effects such as blood clots...

This week, we feature J&J’s Talc litigation closure,Emergent’s strategic changes for growth ,Pfizer’s breakthrough hemophilia B gene therapy approval,Novartis’s strategic Mariana Oncology Buyout, and Beyfortus Breakthrough RSV prevention.

View More Videos
Follow RTT